Singulex’s Assay for Cardiovascular Risk Assessment Highlighted in Two Presentations at AHA 2013 Scientific Sessions

-- Cardiac troponin-I shown to be predictor of cardiovascular risk in two patient populations when measured using Singulex’s ultrasensitive Single Molecule Counting Technology --

AHA Scientific Sessions 2013

ALAMEDA, Calif.--()--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced new data highlighting the Company’s ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart failure (HF) patients. The data were presented at the American Heart Association Scientific Sessions in Dallas, Texas.

The research (Abstract #14247/1054, The Cardiac-Specific Troponin-I Predicts the Burden of Coronary Artery Atherosclerosis in Rheumatoid Arthritis) led by Matthew Budoff, M.D., Professor of Medicine at the David Geffen School of Medicine at UCLA and Director of Cardiac CT at Harbor-UCLA Medical Center, demonstrated that the concentration of cTnI, measured using Erenna, was directly associated with the severity of coronary artery disease in patients with RA. cTnI concentrations were found to be as predictive of coronary atherosclerosis as traditional cardiovascular tests, including coronary artery calcification (p=0.013), segmental stenosis score (p=0.024), segmental involvement score (p=0.019) and plaque burden score (p=0.029), measured via Multi-detector Computed tomography calcium scoring and non-invasive angiography.

“Patients with rheumatoid arthritis are known to be at a 3-fold increased risk for developing cardiovascular disease. However, the challenge is to easily identify which of these patients have disease and treat them accordingly,” said Dr. Budoff. “Our research shows that the ability to measure extremely low levels of cTnI via a simple blood test enables physicians to determine the extent of coronary artery disease in rheumatoid arthritis patients. Using this information, physicians can create proactive treatment plans, ultimately providing better care to patients.”

The study (Abstract #14953/5041, Serial Measurement of an Ultrasensitive Cardiac Troponin-I Predicts Cardiovascular Outcomes and Ventricular Remodeling in Chronic Heart Failure) led by James Januzzi, Jr., M.D., Director, Cardiac Intensive Care Unit at Massachusetts General Hospital, demonstrated that serial measurement of cTnI levels was able to predict future cardiac performance and risk in patients with HF. Concentrations of cTnI at baseline, 3 months and 6 months of follow-up were higher in patients with cardiovascular events than in those without (18.0 vs. 8.6 pg/mL, p = 0.003; 16.4 vs. 8.7 pg/mL, p = 0.006; 13.6 vs. 9.3 pg/mL, p = 0.03) while patients with cTnI levels less than 10.88 pg/mL were found to have a lower cardiovascular event rate (p = 0.007).

“Identification of those heart failure patients whose disease will worsen over time is the first step towards slowing the disease’s progression. We found that Singulex’s ultrasensitive cTnI assay can help us identify these at-risk patients,” said Dr. Januzzi. “In addition, we found that examining serial cTnI measurements not only proved more useful than single measurements alone for predicting risk but also recreates the manner in which a patient’s health would be tracked by their doctor. This data shows that ultrasensitive measurement of cTnI over time is an important prognostic factor and provides predictive risk information for patients with heart failure independent of other risk factors.”

About Singulex’s Erenna Platform

Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.

About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.

Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.

Contacts

BrewLife
Media:
Denise Powell, 510-703-9491
dpowell@brewlife.com
or
Blueprint Life Science Group
Investors:
Chris Kim, 415-375-3340
ckim@bplifescience.com

Sharing

Contacts

BrewLife
Media:
Denise Powell, 510-703-9491
dpowell@brewlife.com
or
Blueprint Life Science Group
Investors:
Chris Kim, 415-375-3340
ckim@bplifescience.com